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Epidemiological studies fairly convincingly suggest that higher intakes of fatty ﬁsh and n-3
fatty acids are associated with reduced risk of Alzheimer’s disease (AD). DHA in plasma is
normally positively associated with DHA intake. However, despite being associated with
lower ﬁsh and DHA intake, unexpectedly, plasma (or brain) DHA is frequently not lower
in AD. This review will highlight some metabolic and physiological factors such as ageing
and apoE polymorphism that inﬂuence DHA homeostasis. Compared with young adults,
blood DHA is often slightly but signiﬁcantly higher in older adults without any age-related
cognitive decline. Higher plasma DHA in older adults could be a sign that their ﬁsh or DHA
intake is higher. However, our supplementation and carbon-13 tracer studies also show
that DHA metabolism, e.g. transit through the plasma, apparent retroconversion and β-
oxidation, is altered in healthy older compared with healthy young adults. ApoE4 increases
the risk of AD, possibly in part because it too changes DHA homeostasis. Therefore, inde-
pendent of differences in ﬁsh intake, changing DHA homeostasis may tend to obscure
the relationship between DHA intake and plasma DHA which, in turn, may contribute
to making older adults more susceptible to cognitive decline despite older adults having
similar or sometimes higher plasma DHA than in younger adults. In conclusion, recent
development of new tools such as isotopically labelled DHA to study DHA metabolism
in human subjects highlights some promising avenues to evaluate how and why DHA
metabolism changes during ageing and AD.
Alzheimer’s disease: Docosahexaenoic acid: Ageing: ApoE: Cognition
The cognitive and psychological health of older adults is
now a major preoccupation for healthcare services and
researchers alike. Alzheimer’s disease (AD) is the main
form of cognitive decline in older persons in Western
countries(1). Age is the main risk factor associated with
AD(1), but other factors also have an effect such as a pre-
disposing genetic polymorphism, i.e. ε4 allele of apoE4(2),
vascular risk factors including hypertension, obesity and
type 2 diabetes(1), and lifestyle including physical activity
and dietary habits(3,4). Among the nutrients closely asso-
ciated with brain function, the n-3 fatty acids, especially
DHA, have attracted special attention. Fatty ﬁsh and
seafood are the most important dietary sources of both
DHA and EPA. DHA is by far the predominant n-3
fatty acid in the brain and is present mostly in various
membrane phospholipids (PL) of neurons, especially in
synapses(5). In contrast to other common dietary long-
chain fatty acids, DHA is highly conserved and poorly
β-oxidised(6–8). In human subjects, DHA synthesis is rela-
tively inefﬁcient, especially in comparison to rodents(9).
Low intake of n-3 fatty acids has long been associated
with higher risk of CVD(10), and also of suboptimal brain
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development(11). Much effort has been focused over the
past decade on whether a higher DHA intake could
decrease the risk of cognitive decline in older adults, or
reduce the progression from mild cognitive impairment
towards AD. In general, these studies polarise in two
directions: randomised clinical trials that are largely
negative and epidemiological studies that are more posi-
tive(12) about the DHA’s role in maintaining cognition
during ageing. Thus, in general, DHA supplementation
trials in AD (with or without EPA) have not so far pro-
duced any truly positive results(12–15). Methodological
issues such as dose of n-3 fatty acid, duration of treat-
ment or selection criteria may well have affected the out-
comes of these trials. DHA supplementation may have a
greater positive effect on memory and learning in healthy
adults(16), elderly with subjective cognitive complaints(17)
or with mild cognitive impairment(18) than in those
with AD(12,14,19). However, prospective epidemiological
studies have been more positive; they broadly show
that habitually low intake of ﬁsh and/or DHA is associ-
ated with higher risk of developing AD(12,20,21). These
results are supported by the neuroprotective role of
DHA reported for non-human models of neurodegenera-
tive disease(22–26).
Studies with biological samples (human blood
and brain) may be able to provide useful leads to ex-
plain the divergent results between randomised clinical
trials and epidemiological studies. We have previously
reviewed at some length the methodological limits on
observational or intervention studies on DHA sup-
plementation in older adults or in AD(12–15,20,21,27); so
we will review them here only brieﬂy. We will also pre-
sent an emerging framework showing that DHA homo-
eostasis changes in older adults and differs in carriers
from non-carriers of apoE4, probably before the onset
of cognitive decline.
DHA in plasma and post-mortem human brain
Brain DHA
In primate, pig and rodent models, when n-3 intake is
severely deﬁcient for extended periods, brain DHA also
decreases across all cell types and regions, in association
with lower scores on cognitive and behavioural
tests(25,28–31). AD is now widely associated with
lower ﬁsh and DHA intake, so it would be logical that
post-mortem brain samples of patients with a deﬁnitive
diagnosis of AD also contained lower DHA. Indeed, in
the hippocampus, which is central to memory processing
and learning, AD patients reportedly do have lower
DHA(32,33). However, in the temporal and frontal cor-
tices which are also affected in AD, DHA is almost
always the same as in the controls (Fig. 1). Studies re-
porting lower DHA in the AD brain show that other
fatty acids are also lower, particularly n-6
PUFA(35,41,44,46). Thus, the effect of AD is not speciﬁc
to DHA which is contrary to what would be expected
if only n-3 fatty acid intake were deﬁcient.
There are many potential methodological reasons for
the observed lack of agreement between the apparently
low DHA intakes in AD yet frequently normal DHA
levels in the brain(12). Crucial among these are the
‘healthy’ controls against which the AD cases are com-
pared as well as the very marked extent of regional
brain atrophy associated with ageing regardless of the
presence of neurological disease(44,50). Furthermore, the
basis for classifying a patient as having AD, i.e. whether
on clinical cognitive criteria or on neuropathological
score, may not give consistent results since senile plaques
are increasingly recognised as being present in a signiﬁ-
cant proportion of cognitively normal elderly per-
sons(51–53). Hence, there is a risk that post-mortem
samples from brain banks for which cognitive status is
not known at the time of death could be misclassiﬁed if
based solely on neuropathological scores. It also appears
that membrane PL in the cortex can tenaciously retain
DHA and that a more discrete and speciﬁc subcellular
pool or membrane pool of DHA may have to be
measured(43). Brain membrane DHA cycles rapidly be-
tween PL and free DHA via DHA-CoA(54,55), and the
deteriorating efﬁcacy of this process could theoretically
contribute to the neurodegenerative processes. Thus, the
key issue in relation to post-mortem tissue analysis is
that the time to lipid extraction is rarely less than 4–5h
yet DHA turnover is on the order of minutes, if not
seconds. Since the turnover of DHA towards resolvins
and neuroprotectins are orders of magnitude lower than
the amount of DHA in the brain NEFA pool, truly
‘physiological’ amounts of these products are extremely
difﬁcult to measure, especially in human subjects(23,56).
As also noted elsewhere, these and other issues severely
constrain the validity and hence the utility of DHA
measurements on human post-mortem brain samples(57).
Fig. 1. Summary of the published literature on brain and blood
DHA in Alzheimer’s disease. The symbols represent the results of
individual studies using each study’s control group as the
reference (100%; dotted line). The papers from which these DHA
data are obtained are as follows: A, Arsenault et al.(34); B, Astarita
et al.(35); C, Boston et al.(36); D, Brooksbank et al.(37); E, Cherubini
et al.(38); F, Conquer et al.(39); G, Corrigan et al.(40); H, Corrigan
et al.(41); I, Cunnane et al.(42); J, Fraser et al.(43); K, Guan et al.(44);
L, Laurin et al.(45); M, Prasad et al.(46); N, Selley et al.(47); O, Skinner
et al.(48); P, Söderberg et al.(32); Q, Tully et al.(49). F,T,P, frontal,
temporal and/or parietal cortex; P-H, para-hippocampus;
H, hippocampus; P-TFA, plasma total fatty acids; P-PL, plasma
phospholipids; P-CE, plasma cholesteryl esters; RBC, red blood
cells.
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Lower DHA would normally be expected in the blood
of those with habitually low DHA intake (whether diag-
nosed with AD or not). In some AD studies, lower DHA
is indeed reported for plasma total lipids(38), PL(39,40,42),
cholesteryl esters(49) and NEFA(58). However, many
other AD studies show no difference in plasma DHA,
whether in PL or total fatty acids(34,38,42,45,59). Some
even report higher DHA in plasma PL(45) or cholesteryl
esters (CE)(40,42). Similar inconsistencies are present
across DHA levels reported for the erythrocytes in AD
(Fig. 1)(36,40,47). Prospective studies also show this
inconsistency: some found a strong association between
lower blood DHA level and slower cognitive decline(60)
or lower risk of dementia(61), whereas other did
not(45,59,62). It may be that the cognitive domain
studied(63,64) and apoE4 genotype(65,66) contribute to
this scatter in the data.
DHA homeostasis during ageing and apoE
We propose that even when collected under hypotheti-
cally ideal conditions (zero delay; perfectly matched,
cognitively healthy controls, etc.), data obtained from
single blood samples are too limited to fully understand
possible changes in DHA metabolism due to genotype,
ageing or neurodegenerative disease. However, isotopi-
cally labelled DHA is emerging as a useful tool to assess
how the metabolism of DHA changes with age. Indeed,
in a relatively simple study design, it was clear that the
clearance of a 50mg oral dose of uniformly carbon-13
labelled DHA (13C-DHA) from the blood over
1 month was much slower in healthy 76-year-old com-
pared with 27-year-old adults(67). These results were simi-
lar to our earlier report that the increase in plasma DHA
during a short-term treatment with ﬁsh oil was higher
in healthy older persons(68). 13C-DHA enrichment in
plasma NEFA and TAG of older adults was most
affected (four- to ﬁvefold higher than in the young
adults) but its enrichment in PL and CE 13C-DHA was
also affected. The doubling of 13C-DHA enrichment in
plasma PL and CE emerged only after about 7d post-
dose, suggesting slower DHA clearance through plasma
lipid classes, i.e. an altered plasma ‘DHA wave’ in
older adults (Fig. 2)(67).
Clearly, therefore, healthy ageing seems to change
DHA metabolism and, hence, homeostasis in human
subjects. Notwithstanding the limited extent to which
the kinetic behaviour of a tracer can be compared with
a single plasma fatty acid measurement, the difference
in 13C-DHA homeostasis in the elderly seems to reﬂect
the results observed in two studies in which lower
DHA was reported in plasma PL yet higher DHA was
reported in plasma CE of AD patients(40,42). The mini-
mally invasive nature of this type of experiment makes
it difﬁcult to invoke a particular mechanism but one
could speculate that the changing sensitivity of endo-
thelial lipoprotein lipase could be involved in this
age-associated difference in DHA homeostasis(69).
ApoE4 carriers are at signiﬁcantly higher risk
of AD(70,71). It is now emerging that the apoE4 status
also affects DHA metabolism in human subjects(27,72,73).
This interaction may help explain why the protective
association of higher dietary intake of ﬁsh(74,75) or higher
erythrocyte total n-3 fatty acids(65) is generally limited to
non-carriers of apoE4. Measuring expired 13C-CO2 after
dosing with 13C-DHA permits the estimation of the
whole body half-life of DHA in healthy older adults,
which is of the order of 32d in carriers of apoE4 and
140d in non-carriers of apoE4(72). Ageing seems not to
affect the whole body half-life of DHA although the
small sample size makes these results still somewhat
preliminary(67).
Using positron emission tomography and the tracer,
11C-DHA, human brain turnover of DHA has been esti-
mated to be about 4mg/d, giving rise to a half-life of
brain DHA of about 2·5 years(54). Hence, the half-life of
brain DHA is much longer than its whole body half-life.
Perhaps further assessments of the brain or whole body
half-life of DHA could provide some insight into the cur-
rent ineffectiveness of DHA supplements in AD despite
the fact that these supplements typically supply several
fold the brain’s apparent daily turnover of DHA(12).
ApoE4 seems also to supress the plasma DHA
response to a ﬁsh oil supplement(73) and the metabolism
of an oral dose of 13C-DHA(72), an effect somewhat op-
posite to that observed with healthy ageing. For up to
28d after a single oral dose of 13C-DHA, carriers of
apoE4 have a slightly lower concentration of plasma
13C-DHA compared with non-carriers(72). When the tra-
cer is given both before and again after a 5-month period
Fig. 2. Delayed plasma clearance of carbon 13-labelled DHA
(13C-DHA) during healthy ageing, adapted from Plourde et al.(67).
Plasma 13C-DHA concentration was followed over 28d after the
oral administration of a single 50mg dose of 13C-DHA in young
(27 years; n 6) and elderly (76 years; n 6) participants. In older
adults, plasma tracer concentration in NEFA and TAG was four to
ﬁvefold higher 4h after giving the oral dose and about twofold
higher 1–4 weeks later in phospholipids (PL) and cholesteryl
esters (CE).
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of DHA+EPA supplementation, the apoE4 carriers had
a greater accumulation of the tracer in plasma after sup-
plementation compared with the non-carriers, again
suggesting slower clearance of DHA to and/or use by
tissues (Fig. 3). Hence, two established risk factors for
AD (ageing and apoE4) both signiﬁcantly change DHA
homeostasis but possibly in different ways.
Linking dietary and plasma DHA
Habitual DHA intake is commonly estimated to be
<250mg/d(76–78) but this is a difﬁcult and laborious
measurement and subject to high day-to-day variability
depending on the frequency of ﬁsh or shellﬁsh con-
sumption. Hence, it would be useful if DHA intake
and plasma DHA were highly correlated because plasma
DHA measurement is now technically simple and
reliable, so it could potentially be a surrogate for dietary
DHA measurement. There is indeed a good positive
correlation between dietary and plasma intake for
DHA consumption, especially at DHA intakes towards
1000mg/d, during which plasma DHA rises to a maxi-
mum of about 4 % in plasma total lipids. However,
DHA always seems to be present in plasma, even when
DHA intake is negligible; thus, vegans consuming no
known dietary sources of DHA still have about 0·5%
DHA in plasma total lipids(79). The problem is that
there are relatively few reports on which to build the
relationship of dietary to plasma DHA. At DHA intakes
between 0 and 50mg/d, DHA is between 0·5 and 1·2 % of
plasma total lipids, but the spread in these data is
large(57). A value of 0·5% DHA in plasma total lipids
therefore seems to be at or close to the lower limit poss-
ible of plasma DHA in healthy adults.
The AD cases we have studied had 1·0% DHA in
plasma total lipids, which empirically corroborates very
low DHA intake, yet they had ‘normal’ DHA in the
PL of brain cortical grey matter(42). Plasma DHA does
not rise in human subjects given EPA or α-linolenic
acid supplements, even in vegans(80–82). The conundrum
therefore is: how are plasma (or brain) DHA levels main-
tained when DHA intakes are very low to negligible? We
speculate that with changes in DHA metabolism and
homeostasis during age-related cognitive decline, the
diet–plasma relation of DHA may shift, explaining why
with lower DHA intake, a population with age-related
cognitive decline appears to have the same plasma
DHA concentration as healthy elderly even though the
availability of DHA to the tissues may be reduced(83).
The lack of an established reference lipid class in blood
(PL, CE, TAG or NEFA, erythrocytes, etc.) for DHA
measurements relative to intake still hampers the extent
to which plasma DHA data from various reports can
be compared in relation to ageing, genotype and risk of
cognitive decline. This area clearly needs further research
but sufﬁce it to say that it is becoming increasingly
important to take into account changing DHA homeo-
stasis in the study of ageing population, especially in a
context of age-related cognitive decline or AD.
Conclusion
We have sought to brieﬂy highlight some of the meth-
odological challenges and potential future directions for
the study of DHA in ageing and AD. The emerging evi-
dence for changing DHA half-life in older adults and in
carriers of apoE4 should encourage more basic research
on DHA metabolism in human subjects. Molecular, cel-
lular and animal models have contributed enormously to
understanding the complexity of DHA biology, but none
of them seem to represent the changes in DHA homeo-
stasis reported in elderly human subjects. The human
brain is able to strongly retain DHA in membrane PL
despite very low DHA intake and advanced AD(42), so
the classical dietary n-3 deﬁciency model used to probe
the function of DHA in the animal brain appears inap-
propriate for research into AD. In human subjects,
DHA in the post-mortem brain is unlikely to correctly
reﬂect what is happening during ageing and AD, due
to its fast turnover in neuronal membrane PL. Ageing-
and apoE4-associated changes in DHA metabolism
strongly suggest altered DHA homeostasis involving a
decrease in plasma DHA clearance during age-related
cognitive decline and AD. Therefore, a shift in the
relationship between plasma and dietary DHA may be
occurring during age-related cognitive decline and AD,
one that needs to be considered when looking at plasma
DHA as a measure of dietary DHA intake. In the future,
the availability of innovative tools for studies of DHA
half-life and metabolism in human subjects will be
needed to understand in a better manner the changes in
DHA metabolism occurring during human ageing and
AD and the potential protective role of DHA on cogni-
tive decline. As shown in prospective studies, a protective
role of DHA in cognitive health of older persons may
depend on consuming a healthy diet throughout adult
life.
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Fig. 3. Plasma carbon 13-labelled DHA (13C-DHA) concentration
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non-carriers (apoE4-; ●).
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